KRAS and pancreatic adenocarcinoma: Of note, we also found B7-H3–high pancreatic adenocarcinomas to display fewer inactivating mutations in RNF43, which has recently been shown to accelerate the progression of KRAS-driven pancreatic neoplasia (32).